Table 1.

Demographics of patients enrolled in the phase II trial of regorafenib and PF-03446962

All percentages: column	Cohort				All
	Level − 1		Level 1
	N	%	N	%	N	%
All	4	100.0	7	100.0	11		100.0
Age, mean (std)	50.4	17.0	62.8	13.4	58.3		15.3
Race
Black or African–American	3	75.0	3	42.9	6		54.5
White	1	25.0	4	57.1	5		45.5
Ethnicity
Not Hispanic or Latino	4	100.0	7	100.0	11		100.0
Gender
Female	1	25.0	3	42.9	4		36.4
Male	3	75.0	4	57.1	7		63.6
Diagnosis
Colon	4	100.0	6	85.7	10		90.9
Rectum	0	0.0	1	14.3	1		9.1